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STATEMENT OF THE PROBLEM
So many genes, so few therapies. This 
meeting* arose from the perception of 
the organizers that there are many dis-
crete and hopefully correctable causes 
for the failure of discoveries in academ-
ic laboratories to result in new thera-
pies. The immediate concern was for 
genodermatoses, individually rare dis-
orders that in the aggregate are respon-
sible for very substantial morbidity and 
mortality. Despite the identification of 
responsible gene mutations and often 
detailed understanding of the patho-
physiology, effective therapies are still 
largely unavailable.
STRUCTURE OF THE MEETING
The two-day meeting consisted of eight 
sessions focused on discrete topics rele-
vant to the development of molecularly 
targeted therapeutics for heritable skin 
diseases, followed by four breakout 
discussion groups and a final joint ses-
sion for review of the group reports and 
consensus building with regard to next 
steps. The 30 speakers, representing 
critical nodal points in the drug devel-
opment process, were invited to submit 
reading lists in advance. These lists and 
“slides” from most of the presentations 
are available at the conference web 
site (http://www.obstacles.medschool.
ucsf.edu). Speakers identified problems 
that they had encountered in their work 
or that they perceived to be issues for 
development of therapies for rare skin 
diseases. Group discussion during each 
session was facilitated by a moderator, 
also expert in the topic area.
The meeting had its genesis in a dis-
cussion among members of the medi-
cal and scientific advisory board of the 
Foundation for Ichthyosis and Related 
Skin Types (FIRST) concerning how to 
stimulate translational research in rare 
skin disease. Support was provided by 
a conference grant from the National 
Institutes of Health (National Institute 
of Arthritis and Musculoskeletal and 
Skin Diseases (NIAMS)) as well as by 
AGI Dermatics, the American Academy 
of Dermatology, the American Skin 
Association, Amgen, the BCCNS Life 
Support Network, DebRA of America, 
FIRST, Genentech, the Pachyonychia 
Congenita Project, Sirna Therapeutics, 
and the Skin Cancer/Organ Transplant 
Program Project Grant (NIAMS).
The invited speakers, many of whom 
had no previous involvement with skin 
science, as well as session modera-
tors, scribes, and other attendees, total-
ing 140 persons, broadly represented 
patients, patient support groups, phy-
sicians, scientists, academics, large 
pharmaceutical companies, small bio-
tech companies, venture capitalists, the 
National Institutes of Health (NIH) as a 
major funding agency, and the United 
States Food and Drug Administration 
(FDA) as the government regulatory 
agency. There was strong representa-
tion of senior dermatologists from both 
the United States and the European 
Union, providing a broad perspective 
on the translational research process. 
The first one-and-a-half days of the 
meeting were designed to familiarize 
participants with the various aspects 
of the drug development process and 
to highlight several areas of promising 
new approaches to treatment of rare, 
monogenic skin disease. The final half 
day was spent in discussion intended to 
separate real from perceived obstacles 
and to prioritize potential pathways to 
reduce those obstacles.
THE FOLLOWING TOPICS WERE 
ADDRESSED IN DISCRETE SESSIONS:
Drug development pathways
Anthony Quinn (Roche, Palo Alto, CA) 
and Seth Stevens (Amgen, Thousand 
Oaks, CA) set the stage for ensuing 
discussion by outlining the usual steps 
in the drug development process and 
the kinds of obstacles that might be 
encountered at each stage. During 
the general discussion it became clear 
that there is a recent tendency for large 
pharmaceutical companies to enter 
drug development at increasingly later 
stages. Quinn emphasized that drug dis-
covery and development is a complex 
process with many potential pitfalls; it 
requires a knowledge base that is dis-
tinct from that of academic medicine, 
and success often depends on effective 
multidisciplinary work. Stevens was the 
first of many to emphasize that interdis-
ciplinary teams are critical to the devel-
opment process.
Financial issues
Luke Evnin (MPM Capital, South San 
Francisco, CA), Geert Cauwenbergh 
(Barrier Therapeutics, Princeton, NJ), 
Lorne Taichman (State University of New 
York, Stony Brook/NY), and Howard 
Welgus (Pfizer, Ann Arbor, MI) repre-
sented, respectively, venture capital, 
a small pharmaceutical company, and 
two large pharmaceutical companies 
with established interests in skin. Evnin 
identified crucial factors that attract 
the various types of potential investors 
and the stage of development at which 
they might be willing to invest. Unmet 
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needs, a plethora of which are found in 
rare skin disease, are a recurring focus 
of venture capital. Welgus reported 
that Pfizer was interested in bringing 
forth novel prescription pharmaceuti-
cals for the treatment of common skin 
diseases and conditions. Big pharma’s 
enthusiasm for therapies against rare, 
inherited disorders would be height-
ened if the targeted genes were found 
to have medical applicability to more 
common conditions. Cauwenbergh 
suggested that the regulatory scales had 
been tipped toward concern for risk 
as opposed to need for new drugs and 
noted that this imbalance was a serious 
disincentive for investors in drugs for 
rare diseases. Suggestions for righting 
the balance included extension of time 
for market exclusivity for such drugs; 
conditional trial approvals restricted to 
patients with the targeted disease with 
frequent review; and extension of the 
authority of the Orphan Drug Division 
of the FDA. Taichman advised the audi-
ence to think like an investor, not like a 
convert. He gave examples of how cell-
based gene therapies faced particularly 
difficult regulatory hurdles because of 
the complexity of production issues. All 
emphasized that demonstrated efficacy 
in humans increasingly was expected 
by investors of all stripes.
Regulatory processes
Jonathan Wilkin (formerly FDA, 
Rocksville, MD) outlined the usual 
regulatory steps that apply to derma-
tologics. He urged developers to look 
beyond the “targeted” nature of the 
drug and seek empiric evidence for 
safety and effectiveness. Drugs intend-
ed for chronic use will receive addi-
tional scrutiny. Marlene Haffner (Office 
of Orphan Products Development, 
FDA, Rockville, MD) identified the 
special rules that apply to the develop-
ment of orphan drugs. She indicated 
that her office exists to help the patient 
and the researcher. She gave examples 
of special programs her office uses to 
assist in the development of products 
to treat rare diseases. She noted that a 
common cause for delay in the regula-
tory approval process was poor under-
standing of the natural history or basic 
science of the disease, which leads to 
inappropriate endpoints. There was 
discussion of how small numbers of 
patients scattered over great distances 
add layers of complexity to logistics 
and to the institutional review board 
approval process.
Small molecules for rare diseases
Fred de Sauvage (Genentech, South 
San Francisco, CA) described drug 
development targeted to the hedgehog 
pathway, emphasizing how increased 
understanding of complex biology 
both limits and dictates developmental 
efforts. John Reed (Burnham Institute, 
La Jolla, CA) described the new NIH ini-
tiative (the Molecular Library Screening 
Center Network) designed to help 
investigators to get over the hurdles of 
rapid throughput assay development, to 
identify lead molecules, and to encour-
age collaboration between academic 
institutions. Irwin McLean (University 
of Dundee, UK) described early stages 
of screening of small-molecule libraries 
for transcriptional regulators of keratin 
6a expression.
Protein therapeutics
Emil Kakkis (BioMarin, Novato, CA) 
described the stirring odyssey of the 
development of Cerezyme, a pro-
tein replacement therapy for Hurler’s 
disease which affects about 3,000 
patients worldwide. Mark Sliwkowski 
(Genentech, South San Francisco, CA) 
spoke about Herceptin, a protein thera-
peutic targeted to a much larger market 
(breast cancer patients) that nevertheless 
might have been abandoned if under-
standing of the biology of the disease 
had not kept pace with the develop-
ment process. Both speakers described 
the technical, regulatory, and financial 
hurdles encountered in bringing system-
ically administered protein therapeutics 
to market. Dan Yarosh (AGI Dermatics, 
Freeport, NY) spoke about the difficul-
ties of getting a topical protein thera-
peutic, T4 endonuclease V (T4N5), to 
market for xeroderma pigmentosum 
and the need for separate new investi-
gational new drug applications (INDs) 
for individual disease indications. 
His comments made clear that FDA 
approval is sometimes elusive, despite 
apparent intentions to the contrary. 
David Woodley (University of Southern 
California, Los Angeles) spoke about 
preclinical success of injected collagen 
VII in animals with recessive dystrophic 
epidermolysis bullosa. He indicated that 
he would be ready to do human clinical 
trials, if he could make large amounts 
of the protein in a good manufacturing 
practice (GMP) facility. As happens so 
often, that last critical production step 
is beyond the resources of a university-
based laboratory, and the small size of 
the target patient population discour-
ages investors. Heiko Traupe (University 
of Münster, Germany) described early 
efforts to produce biologically active 
transglutaminase 1 for replacement in 
lamellar ichthyosis.
Targeting translation/transcription
Several methods for reduction of specif-
ic mRNA targets were presented. Joseph 
Carroll (Sirna Therapeutics, Boulder, 
CO) has used small interfering RNA 
(siRNA) to deplete the hr transcription 
factor, which in turn depletes mRNAs 
necessary for hair growth. His com-
pany has a phase I trial of siRNA ongo-
ing in macular degeneration, and he 
discussed the medicinal chemistry and 
formulation needed to improve phar-
macokinetics and to secure intellec-
tual property rights. Frank Bennett (Isis 
Pharmaceuticals, Carlsbad, CA) report-
ed that there has been tremendous prog-
ress in advancing antisense technology 
for the treatment of many systemic dis-
eases. Local delivery, however, to cells 
in the skin by either systemic or topical 
routes remains an issue. He described 
an antisense RNA that led to substantial 
depletion of ICAM expression in epider-
mis in preclinical models but failed to 
have a significant effect when applied 
topically to patients with psoriasis. He 
indicated that failure to translate ani-
mal experience to human disease can 
be related to poor understanding of the 
role of the target in human disease or to 
differences in delivery parameters in 
animals compared with humans. He 
suggested that companies such as his are 
often willing to provide technology to 
funded investigators, who are interested 
in clinically well-understood targets and 
have potential investors standing by. He 
gave examples of ongoing collaborative 
trials targeting SOD1 inamyotrophiclat-
eral sclerosis and apolipoprotein B in 
familial hyperlipidemia. Roger Kaspar 
E Epstein et al.
Obstacles to Translation Conference
1436 Journal of Investigative Dermatology (2006), Volume 126
(TransDerm, Santa Cruz, CA) described 
siRNA suppression of mutant keratin, 6a 
in vitro, and long-lived suppression of 
reporter gene expression in mouse epi-
dermis following intradermal injection. 
Moving those promising observations to 
trial in patients with pachyonychia con-
genita is his immediate challenge.
Targeting DNA
Peter Glazer (Yale University, New 
Haven, CT) talked about using triplex-
forming oligonucleotides, and Michael 
Holmes (Sangamo, Boulder, CO) talked 
about using zinc-finger nucleases to 
recruit DNA repair enzymes in conjunc-
tion with simultaneously administered, 
homologous donor oligonucleotides to 
introduce site-specific sequence changes 
in DNA. Stable correction in cell lines 
and in mouse models has been achieved 
by both methods. Delivery issues are in 
large part responsible for low efficiency 
but can theoretically be overcome by 
repeated treatment or biological selec-
tion of the targeted cells. Paul Khavari 
(Stanford University, Stanford, CA) gave 
two examples of preclinical success 
using lentiviral vectors: replacement of 
transglutaminase 1 in cells from patients 
with lamellar ichthyosis and of collagen 
VII in fibroblasts from patients with reces-
sive dystrophic epidermolysis bullosa. 
Unfortunately, scale-up issues and the 
regulatory climate following several viral 
vector-related adverse events in other 
clinical trials have impeded movement 
of that work into the clinic. One poten-
tial technical obstacle for certain types of 
in vivo gene therapy will be low-efficien-
cy methods that target less than 100% of 
cells. When new genes are introduced 
into keratinocytes or fibroblasts, loss of 
gene expression has been a repeatedly 
observed problem. One reason for lost 
expression is that targeted cells have no 
selective advantage over normal cells. 
Jonathan Vogel (NIH, Bethesda, MD) 
showed that co-introduction of a select-
able marker the multidrug resistance 
gene (MDR), with the target gene, fol-
lowed by topical selection with colchi-
cine, resulted in improved percentage 
and persistence of gene-targeted cells.
Miscellaneous issues
Sherri Bale (GeneDx, Gaithersburg, 
MD) spoke about how genetic het-
erogeneity in clinical diagnosis might 
affect the success and evaluation of 
therapeutic trials. Dennis Roop (Baylor 
College of Medicine, Houston, TX) 
described the value of engineered 
mouse models both for understand-
ing of the pathophysiology of genetic 
skin disease and for preclinical testing. 
Discussion focused on the encourage-
ment investigators take from success in 
animal models contrasted with the not 
infrequent failure of animal models to 
predict success in the clinic, and the 
current reluctance of venture capital 
and industry to join a translational effort 
until success in humans has been estab-
lished. Soosan Ghazizideh (Columbia 
University, New York, NY) described 
how immune responses are likely 
to limit the effectiveness of cutane-
ous gene therapy and emphasized the 
need for studies directed at modulating 
destructive immune responses. Eugene 
Bauer (Neosil, Emeryville, CA, and for-
merly Stanford University, Stanford, 
CA) described how academic, industry, 
and regulatory cultures and policies 
(including those regarding conflicts 
of interest) impede the translation of 
basic discoveries to innovative patient 
therapies. He provided examples of 
how misunderstanding, mistrust, and 
disrespect between those cultures can 
impede translational research. Steve 
Katz (NIH, Bethesda, MD) outlined the 
new NIH road map and described new 
NIH initiatives designed to promote 
translational research. NIH acceptance 
of central institutional review boards 
for clinical trials could have a role in 
facilitating rare-disease trials. Margaret 
Kripke (MD Anderson Cancer Center, 
Houston, TX) described how and why 
the university research community 
discourages a teamwork approach to 
research. She noted that the President’s 
Council on Cancer Research has sug-
gested several areas in which a new 
system of rewards might begin to solve 
that problem: seed money, publication 
and grant review, and priority for col-
laborative research.
BREAKOUT DISCUSSIONS AND 
CONCLUDING SESSION
Conference speakers and attendees 
were assigned or self-assigned to one 
of four discussion groups after the last 
of the eight plenary sessions to distill 
the issues discussed, to consider what 
might be done, and finally to make rec-
ommendations for group action. The 
assigned topics were Obstacles to Drug 
Discovery (Paul Nghiem, moderator), 
Obstacles to Translation of Promising 
Therapies (Irene Leigh, moderator), 
Obstacles in Institutional Cultures 
(Kevin Cooper, moderator), and 
Obstacles to Gathering Funds (Klaus 
Wolff, moderator). These deliberations, 
also available on the conference web 
site (http://www.obstacles.medschool.
ucsf.edu), were summarized for each 
group by its designated group leader. 
At the final joint session, the following 
conclusions received strong support:
Focus
We are overly rich in molecularly 
defined, rare skin diseases worthy of 
treatment. There are also many prom-
ising, unique, and complementary 
technologies poised for clinical devel-
opment. As a concerned community, 
the participants recognized that suc-
cessful treatment of a limited number 
of diseases would likely enable more 
rapid translation of treatments for many 
additional diseases. Therefore, concen-
trating resources on a small number of 
clinical targets to achieve proof of con-
cept makes strategic sense.
Educate and communicate
Clear understanding of the biology of 
these rare diseases will be crucial for 
undertaking and completing therapeu-
tic trials. Dermatologists will play a 
central role in that effort, but there are 
few existing models or mechanisms 
for learning the complexities of devis-
ing valid clinical metrics and usher-
ing successful protocols through the 
drug development process or regula-
tory hurdles. Existing dermatological 
institutions should be called upon to 
establish programs for information 
exchange, access to learning resourc-
es, and identification of partners 
willing to help facilitate the complexi-
ties of bringing drugs for rare diseases 
to market.
Devise a novel institutional structure
There is a widening gap between dis-
covery of promising drugs in model 
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systems and sufficient information to 
entice venture capital or industry to 
become involved in the development 
effort. No existing institutional struc-
tures are ideally suited to bridge this 
gap. Therefore, a new structure may be 
needed to push forward translation of 
products for rare skin disease.
Reward collaboration
Collaboration and cooperation, a cen-
tral feature of the business culture, will 
be critically important if development 
of drugs is to become routine rather 
than exceptional. Existing institutions, 
including universities, journals, soci-
eties, and patient support groups, will 
need to move their cultures toward 
reward systems that encourage collab-
orative efforts. Broad institutional and 
regulatory acceptance of central insti-
tutional review boards would be one 
example. Recognizing collaborative 
rather than principal-investigator-style 
research accomplishments through 
promotion and other academic rewards 
would be another.
RECOMMENDATIONS AND NEXT 
STEPS
The very intense and fast-paced nature 
of the conference, held on the eve of 
the Annual Meeting of the American 
Academy of Dermatology, which many 
of the conference participants planned 
to attend, precluded thoughtful diges-
tion of all the information presented. 
Participants have continued to interact 
with the conference organizers and 
each other, but at this writing, much 
remains to be done in order to meet 
the implicit goal of enhancing treat-
ment options for genodermatoses. 
The major conclusion reached by the 
participants was that the conference 
had served a critical catalytic func-
tion in bringing together individuals 
of diverse backgrounds, strongly com-
mitted to translational research and 
specifically to developing therapies for 
genodermatoses, based on recent sci-
entific advances. There was unanimous 
agreement that the exchange among 
the different groups — patients and 
patient advocates, clinicians, physi-
cian-scientists, basic scientists, indus-
try scientists, representatives of the 
biotechnology and pharmaceutical 
industries, federal regulators, funding 
agencies, financiers, venture capitalists, 
and entrepreneurs — was exceedingly 
informative and led to invaluable net-
working at many levels. To capitalize 
on this important beginning, the orga-
nizers are planning a follow-up meet-
ing in the form of a workshop during 
the March 2007 Annual Meeting of the 
American Academy of Dermatology in 
Washington, DC. Details of this meet-
ing will be forthcoming.
*The Obstacles to Translation Conference 
was held at the University of California, 
San Francisco, California, USA, 1–2 March 
2006.
